JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2006; 47:1471-1477, doi:10.1016/j.jacc.2005.11.060 (Published online 14 March 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2005.11.060v1
47/7/1471    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, G. D.
Right arrow Articles by Semigran, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lewis, G. D.
Right arrow Articles by Semigran, M. J.

PRECLINICAL STUDY

Sildenafil Improves Coronary Artery Patency in a Canine Model of Platelet-Mediated Cyclic Coronary Occlusion After Thrombolysis

Gregory D. Lewis, MD*, Christian Witzke, MD*, Pedro Colon-Hernandez, MD*, J. Luis Guerrero*, Kenneth D. Bloch, MD*,{dagger} and Marc J. Semigran, MD*,*

* Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
{dagger} Cardiovascular Research Center of the Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts

Manuscript received July 6, 2005; revised manuscript received November 3, 2005, accepted November 21, 2005.

* Reprint requests and correspondence: Dr. Marc J. Semigran, Cardiology Division, Bigelow 800, Massachusetts General Hospital, Fruit Street, Boston, Massachusetts 02114 (Email: msemigran{at}partners.org).

OBJECTIVES: We sought to assess the effect of sildenafil, a highly-specific type 5 phosphodiesterase (PDE5) inhibitor, on platelet-mediated cyclic coronary flow reductions occurring in a canine model of coronary thrombosis despite aspirin therapy.

BACKGROUND: The PDE5 inhibitors augment the antithrombotic effects of nitric oxide in vitro and in vivo, but it has been proposed that the PDE5 inhibitor sildenafil is prothrombotic.

METHODS: Cyclic coronary flow reductions were induced in the left anterior descending coronary artery by creation of a stenosis, endothelial injury, and thrombus formation followed by treatment with aspirin, heparin, and tissue plasminogen activator. After an initial observation period, dogs were treated with or without sildenafil (100 µg/kg bolus followed by 4 µg/kg/min infusion).

RESULTS: Cyclic coronary flow reductions ceased in five of six animals 18 ± 5 min after initiation of sildenafil but continued in all six control animals. The portion of the observation period during which the coronary artery was patent increased from 52 ± 9% to 83 ± 5% after sildenafil administration (p = 0.008) but did not differ between the first and second observation periods in untreated dogs (49 ± 11% vs. 44 ± 11%, respectively). Among animals with plasma free sildenafil levels ≥20 nmol/l, cyclic coronary flow reductions were 73 ± 12% less frequent and the time to cessation of cycling 72 ± 14% shorter than in animals with levels <20 nmol/l (p < 0.05 for both). Sildenafil transiently decreased blood pressure 7 ± 1% but did not change heart rate. Sildenafil treatment reduced ex vivo thrombin-induced platelet aggregation by 39 ± 3% (p < 0.005).

CONCLUSIONS: Sildenafil improves coronary patency in a canine model of platelet-mediated coronary artery thrombosis, likely via inhibition of platelet aggregation.

Abbreviations and Acronyms
  ACS = acute coronary syndromes
  CAPR = coronary artery patency ratio
  CFR = cyclic coronary flow reductions
  cGMP = cyclic guanosine monophosphate
  GP = glycoprotein
  LAD = left anterior descending coronary artery
  MAP = mean systemic arterial blood pressure
  NO = nitric oxide
  PDE5 = type 5 phosphodiesterase




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
L. S. Wilson, H. S. Elbatarny, S. W. Crawley, B. M. Bennett, and D. H. Maurice
Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions
PNAS, September 9, 2008; 105(36): 13650 - 13655.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.